GlobeImmune Company Profile (NASDAQ:GBIM)

About GlobeImmune (NASDAQ:GBIM)

GlobeImmune logoGlobeImmune, Inc. is a biopharmaceutical company. The Company is focused on developing products for the treatment of cancer and infectious diseases based on its Tarmogen platform. The Company's segment is the business of developing and commercializing various biopharmaceutical products. The Company's infectious disease product candidates include GS-4774, which is in Phase II for the treatment of chronic hepatitis B infection; GI-19000; GI-2010, which is in the preclinical stage of development for the treatment of Human immunodeficiency virus (HIV), and GI-18000, which is in the preclinical stage of development for the treatment of Chronic hepatitis D infection. The Company's oncology product candidates include GI-6207, which is in Phase II for the treatment of medullary thyroid cancer; GI-6301, and GI-4000, which is in Phase IIb for the treatment of Resected pancreas cancer, and in Phase II for the treatment of Non-small cell lung cancer and colorectal cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:GBIM
  • CUSIP: N/A
  • Web:
  • Market Cap: $3.39 million
  • Outstanding Shares: 5,751,000
Average Prices:
  • 50 Day Moving Avg: $0.59
  • 200 Day Moving Avg: $0.42
  • 52 Week Range: $0.11 - $1.98
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $6.21 million
  • Price / Sales: 0.55
  • Book Value: $0.37 per share
  • Price / Book: 1.59
  • EBIDTA: ($1,940,000.00)
  • Net Margins: -91.46%
  • Return on Equity: -134.60%
  • Return on Assets: -32.51%
  • Average Volume: 17,892 shs.
  • Beta: 2.8
  • Short Ratio: 0.1

Frequently Asked Questions for GlobeImmune (NASDAQ:GBIM)

What is GlobeImmune's stock symbol?

GlobeImmune trades on the NASDAQ under the ticker symbol "GBIM."

How were GlobeImmune's earnings last quarter?

GlobeImmune Inc (NASDAQ:GBIM) announced its quarterly earnings results on Thursday, May, 12th. The company reported ($0.15) EPS for the quarter, topping analysts' consensus estimates of ($0.27) by $0.12. The company earned $0.94 million during the quarter. GlobeImmune had a negative return on equity of 134.60% and a negative net margin of 91.46%. View GlobeImmune's Earnings History.

Who are some of GlobeImmune's key competitors?

Who are GlobeImmune's key executives?

GlobeImmune's management team includes the folowing people:

  • J. William Freytag Ph.D., Independent Chairman of the Board
  • Timothy C. Rodell M.D., President, Chief Executive Officer, Director
  • C. Jeffrey Dekker CPA, Vice President - Finance, Treasurer, Secretary
  • Augustine J. Lawlor, Independent Director
  • Daniel J. Mitchell, Independent Director
  • S. Edward Torres, Independent Director

How do I buy GlobeImmune stock?

Shares of GlobeImmune can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GlobeImmune's stock price today?

One share of GlobeImmune stock can currently be purchased for approximately $0.59.

MarketBeat Community Rating for GlobeImmune (NASDAQ GBIM)
Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  22 (Vote Outperform)
Underperform Votes:  26 (Vote Underperform)
Total Votes:  48
MarketBeat's community ratings are surveys of what our community members think about GlobeImmune and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for GlobeImmune (NASDAQ:GBIM) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for GlobeImmune (NASDAQ:GBIM)
No equities research coverage for this company has been tracked by


Earnings History for GlobeImmune (NASDAQ:GBIM)
Earnings by Quarter for GlobeImmune (NASDAQ:GBIM)
Earnings History by Quarter for GlobeImmune (NASDAQ GBIM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/12/2016Q1($0.27)($0.15)$0.94 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for GlobeImmune (NASDAQ:GBIM)

No earnings estimates for this company have been tracked by


Dividend History for GlobeImmune (NASDAQ:GBIM)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for GlobeImmune (NASDAQ:GBIM)
Insider Trades by Quarter for GlobeImmune (NASDAQ:GBIM)
Insider Trades by Quarter for GlobeImmune (NASDAQ:GBIM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/18/2016Augustine LawlorDirectorSell11,000$1.55$17,050.00View SEC Filing  
3/17/2016Daniel J MitchellDirectorSell21,600$1.66$35,856.00View SEC Filing  
3/15/2016Daniel J MitchellDirectorSell130,269$2.26$294,407.94View SEC Filing  
3/11/2016Augustine LawlorDirectorSell16,500$1.60$26,400.00View SEC Filing  
3/10/2016Daniel J MitchellDirectorSell16,400$1.17$19,188.00View SEC Filing  
3/8/2016Augustine LawlorDirectorSell15,010$1.05$15,760.50View SEC Filing  
3/7/2016Daniel J MitchellDirectorSell11,920$1.05$12,516.00View SEC Filing  
3/3/2016Augustine LawlorDirectorSell15,990$1.11$17,748.90View SEC Filing  
3/2/2016Daniel J MitchellDirectorSell17,422$1.02$17,770.44View SEC Filing  
3/1/2016Daniel J MitchellDirectorSell8,799$0.96$8,447.04View SEC Filing  
2/29/2016Augustine LawlorDirectorSell15,000$0.98$14,700.00View SEC Filing  
2/26/2016Daniel J MitchellDirectorSell12,501$1.03$12,876.03View SEC Filing  
2/24/2016Augustine LawlorDirectorSell15,000$1.33$19,950.00View SEC Filing  
2/23/2016Daniel J MitchellDirectorSell22,858$1.42$32,458.36View SEC Filing  
2/22/2016Augustine LawlorDirectorSell5,000$1.43$7,150.00View SEC Filing  
2/19/2016Ventures Vii Lp HealthcareInsiderSell15,000$1.44$21,600.00View SEC Filing  
2/18/2016Daniel J MitchellDirectorSell21,897$1.45$31,750.65View SEC Filing  
2/16/2016Ventures Vii Lp HealthcareMajor ShareholderSell15,000$1.61$24,150.00View SEC Filing  
2/12/2016Daniel J MitchellDirectorSell3,645$1.75$6,378.75View SEC Filing  
2/9/2016Daniel J MitchellDirectorSell7,300$2.05$14,965.00View SEC Filing  
7/8/2014Celgene International IncMajor ShareholderBuy200,000$10.00$2,000,000.00View SEC Filing  
7/8/2014S. Edward TorresDirectorBuy85,000$10.00$850,000.00View SEC Filing  
7/8/2014Timothy C Rodell JrCEOBuy5,000$10.00$50,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for GlobeImmune (NASDAQ:GBIM)
Latest Headlines for GlobeImmune (NASDAQ:GBIM)
DateHeadline logoColorado biotech to restart operations at Louisville facility - August 29 at 7:27 PM logoGlobeImmune (GBIM) Given Daily News Impact Score of 0.12 - April 25 at 8:36 PM logo4:06 pm Globelmmune enters into a definitive purchase agreement for the sale of 12,835,490 shares of its common stock to NantCell a member of the NantWorks ecosystem of companies - March 23 at 10:55 PM logoTENX Awaits Data In Jan, GBIM Hit Hard, FDA Says No To SPPI - November 21 at 10:15 AM logoGilead CEO Resigns, Dumps GlobeImmune Pact (GILD) - November 18 at 4:41 PM logo3:55 am Globelmmune provides corporate update; CEO resigns, Gilead (GILD) terminates collaboration and license agreement - November 18 at 8:01 AM logoMid-Day Market Update: U.S. Stocks Turn Positive; Nortek Shares Surge Following Acquisition News - July 6 at 5:18 PM logoAfter-Hours Stock Movers 07/05: (EGLE) (MDVN) (BIIB) Higher; (GBIM) (VTR) (TSLA) Lower (more...) - July 6 at 5:18 PM logoGLOBEIMMUNE INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; T - July 5 at 4:44 PM logoGlobeImmune Announces Delisting and Deregistration of Common Stock - July 5 at 4:30 PM logoIs this Colorado biotech a takeover target? - June 20 at 11:22 AM logoThese Four Companies Are a Must for Your Watchlist, in June - June 17 at 5:02 PM logoMarkets Rally Belatedly To ECB Bazooka (GBIM) - March 11 at 11:47 AM logoGLOBEIMMUNE INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits - February 23 at 4:12 PM logoGLOBEIMMUNE INC Financials - December 8 at 1:18 PM logoGLOBEIMMUNE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits - November 13 at 9:12 AM logoGlobeImmune Announces Third Quarter 2015 Results and Corporate Highlights - November 13 at 6:30 AM logoGLOBEIMMUNE INC Files SEC form 10-Q, Quarterly Report - November 13 at 6:15 AM logoGlobeImmune Announces Second Quarter 2015 Results and Corporate Highlights - August 14 at 6:30 AM logoGlobeImmune Engages Cantor Fitzgerald as Financial Advisor to Assist With Evaluation of Strategic Options - August 13 at 6:30 AM logoGLOBEIMMUNE INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits - August 4 at 4:29 PM logoGLOBEIMMUNE INC Files SEC form 8-K, Change in Directors or Principal Officers - July 17 at 4:31 PM logoGLOBEIMMUNE INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders - July 13 at 4:12 PM



GlobeImmune (GBIM) Chart for Monday, September, 25, 2017

This page was last updated on 9/25/2017 by Staff